Dapagliflozin is associated with greater reductions in HbA1c and weight than saxagliptin in management of type 2 diabetes mellitus (T2DM). The present post hoc analyses compared the durability of these effects over short-and long-term followup in patients with T2DM who were inadequately controlled with metformin (≥1500 mg/day) and who were receiving either dapagliflozin (10 mg/day) or saxagliptin (5 mg/day). Failure of glycaemiccontrol was assessed using the slope of the change in HbA1c from baseline-over-time regression line (coefficient of failure [CoF]). CoF was compared directly (dapagliflozin vs saxagliptin) over the short term (NCT01606007, 24 weeks) and indirectly (placebo-adjusted) over the long term (NCT00528879 and NCT00121667, 102 weeks). A low CoF value indicated greater durability. CoF was lower for dapagliflozin versus saxagliptin over 18-24 weeks (−1.38%/year; 95% CI, −2.41 to −0.35; P = .009) and 20-102 weeks (−0.37%/year;
weight with an SGLT2 inhibitor as compared to a DPP4 inhibitor. We reviewed data from three phase 3 randomized trials of dapagliflozin versus saxagliptin in patients with type 2 diabetes mellitus (T2DM) (NCT01606007, NCT00528879, NCT00121667) and compared the durability of these effects over short-and long-term follow-up using coefficient of failure (CoF) methodology. 3, 5, 6 2 | METHODS 2.1 | Short term: direct statistical comparison of dapagliflozin and saxagliptin Patients with HbA1c between 8% and 12%, inclusive (64-108 mmol/mol), who were receiving a stable dose of metformin (≥1500 mg/day) were randomized to receive either dapagliflozin (10 mg/day) or saxagliptin (5 mg/day) as add-on therapy. 3 Patients with inadequate glycaemic control from Weeks 6 to 24 were eligible to receive open-label rescue medication (details of rescue criteria in Table S1 ). Patients were included in the CoF analysis if there was at least one change in HbA1c from baseline (ΔHbA1c) value at Week 18 and a repeat value between Week 18 and Week 24 available for them in both the dapagliflozin and saxagliptin groups. Patients with uncontrolled hypertension (SBP ≥160 mm Hg and diastolic blood pressure ≥100 mm Hg), FPG of at least 270 mg/dL during the 4-week lead-in period, cardiovascular disease within 3 months of screening, congestive heart failure (New York Heart Association [NYHA] functional class IV), estimated glomerular filtration rate less than 60 mL/min/1.73 m 2 or serum creatinine of at least 1.5 mg/dL in men and 1.4 mg/dL in women, or significant hepatic disease were excluded. The endpoints assessed included: (a) number of patients with HbA1c above 9% (75 mmol/mol) at Week 24 or who received rescue medication because of failure to achieve pre-specified glycaemic targets or who discontinued treatment because of lack of glycaemic control, and (b) time to rescue medication usage or study discontinuation because of failure to achieve glycaemic targets up to 24 weeks of treatment. Durability of glycaemic control was assessed as CoF for ΔHbA1c, based on an earlier study. 7 CoF was measured using the slope from a random coefficient model of ΔHbA1c over Weeks 18-24, excluding data following rescue medication usage.
| Long term: indirect statistical comparison of dapagliflozin and saxagliptin
Patients receiving either dapagliflozin (10 mg/day) or saxagliptin (5 mg/day) or corresponding placebo plus a stable dose of metformin (≥1500 mg/day) for more than 8 weeks, with HbA1c between 7% and 10%, inclusive (53-86 mmol/mol), C-peptide greater than 1.0 ng/mL, body mass index of 45 kg/m 2 or less for dapagliflozin or 40 kg/m 2 or less for saxagliptin, and serum creatinine of 1.5 mg/dL or less in men and 1.4 mg/dL or less in women were assessed. Metformin uptitration was not permitted in either study. Patients with a lack of glycaemic control from Week 4 to Week 102 were eligible to receive open-label rescue medication. Rescue criteria were similar in both studies (Table S1 ). Data concerning patients who received rescue medication prior to Week 20 and those who received it after Week 20 were excluded from CoF analysis. Data proximal to initiation of treatment, prior to Week 20, were also excluded to allow time for glycation of haemoglobin under treatment. There were at least three 
| Safety
Safety parameters for all three studies 3,5,6 have been reported previously. Adverse events (AEs), serious AEs, and AEs of special interest, including hypoglycaemia, genital infections, and urinary tract infections for studies NCT00528879 and NCT00121667 are summarised herein.
| Statistical analyses
Patients in both the short-and long-term analyses were categorized into two sets: overall (all randomized patients) and CoF (patients included in the CoF analysis). TTSD because of lack of glycaemic control or rescue medication usage because of failure to achieve prespecified glycaemic targets 3,5,6 was assessed using the Kaplan-Meier Cochrane Collaboration, 2014). 8 
| RESULTS
Demographic and baseline characteristics of dapagliflozin-and saxagliptin-treated patients were similar in both the short-and longterm analysis populations (Table S2) .
Dapagliflozin-treated patients showed 6.0% (95% CI, 1.0, 11.0; P < .05) fewer discontinuations because of inadequate glycaemic control or instances of rescue medication usage because of failure to achieve glycaemic targets as compared to saxagliptin-treated patients over 24 weeks. The difference in discontinuations increased to 12.3% (95% CI, 4.5, 20.0; P < .01) when HbA1c greater than 9% (75 mmol/mol) at 24 weeks was added to the above criteria.
Dapagliflozin delayed TTSD or rescue medication usage because of failure to achieve pre-specified glycaemic targets up to Week 24 as compared to saxagliptin ( Figure 1A) . Importantly, dapagliflozin-treated (Figure 2A-C) . The positive effects of dapagliflozin and saxagliptin on SBP were maintained throughout the study ( Figure 2B ). Concerning safety, both dapagliflozin and saxagliptin were generally well tolerated among patients (Table S3 ). Incidences of hypoglycaemia were low in both dapagliflozin-and saxagliptin-treated patients, although the rates of genital and urinary tract infections were higher in dapagliflozin-treated patients than in saxagliptintreated patients.
(C)

| DISCUSSION
The Consistent with the β-cell-independent mechanism of action of dapagliflozin, lower CoF was observed with dapagliflozin than with saxagliptin where efficacy may be limited by reduced β-cell capacity, especially in patients with higher HbA1c. [9] [10] [11] The greater durability of HbA1c control with dapagliflozin versus saxagliptin over 20-102 weeks is consistent with a recent meta-analysis that showed that SGLT2 inhibitors achieved greater efficacy for glycaemic control than DPP4 inhibitors up to 52 weeks. 12 Long-term dapagliflozin treatment in patients with T2DM has achieved glucose-lowering efficacy and associated reductions in blood pressure and body weight across a broad spectrum of patients, including those with cardiovascular and renal comorbidities. 13 Thus, our findings support the long-term efficacy and safety profile of dapagliflozin previously reported, as monotherapy or as an adjunct to metformin in patients with inadequately controlled T2DM.
The similar maintenance of FPG, SBP, and body weight from Rates of hypoglycaemia with either dapagliflozin or saxagliptin were low and comparable to the rates observed with placebo; however, in the long-term analysis, numerically higher rates of both genital and urinary tract infections were noted in dapagliflozin-treated patients as compared to saxagliptin-treated patients, which is consistent with dapagliflozin's mechanism of action and safety profile. 14 A strength of the CoF method is that it allows for use of all collected data, without need for an arbitrary threshold. 15 In addition, the CoF method used reflects both improvement and deterioration of glycaemia. 15 Regarding limitations, the short-term study may not allow sufficient time to adequately assess long-term durability of the efficacy of dapagliflozin as compared to saxagliptin. Moreover, indirect comparisons, while allowing for assessment of long-term relative efficacy, are associated with the potential for greater interference of modifying factors such as intercurrent illness and changes in other medications. 16 Additionally, the CoF method relies on "regression slopes" and does not allow evaluation of conditions of maintained efficacy unaccompanied by incremental worsening or improvement over time. Alternative methods must be considered in such instances.
Finally, in this short-term study, baseline HbA1c of patients was required to be at least 8.0% (64 mmol/mol) and less than 12.0%, inclusive (108 mmol/mol) and, therefore, our analysis may not apply to patients with baseline HbA1c less than 8.0% (64 mmol/mol).
In conclusion, dapagliflozin offered greater durability of glucose control than saxagliptin, in both short-term (head-to-head comparison) and long-term (indirect comparison) analyses. Consistent with lower CoF, dapagliflozin-treated patients had fewer discontinuations or requirements for rescue medication than saxagliptin-treated patients in both short-term and long-term analyses.
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